Published in Gastroenterology on November 01, 1978
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Toxigenic clostridia. Clin Microbiol Rev (1990) 5.40
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg (2002) 4.91
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol (2004) 2.82
Purification and characterization of Clostridium difficile toxin. Infect Immun (1979) 2.71
Transferable tetracycline resistance in Clostridium difficile. Antimicrob Agents Chemother (1981) 2.56
tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49
Rapid detection of Clostridium difficile toxin in human feces. J Clin Microbiol (1980) 2.33
Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun (2009) 2.26
Identification of toxigenic Clostridium difficile by counterimmunoelectrophoresis. J Clin Microbiol (1980) 2.24
Multilocus sequence typing analysis of human and animal Clostridium difficile isolates of various toxigenic types. J Clin Microbiol (2004) 2.11
Simplified procedure for the routine isolation of Clostridium difficile from faeces. J Clin Pathol (1981) 2.07
In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother (1980) 1.89
Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol (1983) 1.89
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol (2002) 1.83
Evaluation of the usefulness of counterimmunoelectrophoresis for diagnosis of Clostridium difficile-associated colitis in clinical specimens. J Clin Microbiol (1983) 1.78
Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (1993) 1.77
Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol (1984) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
Oral metronidazole in Clostridium difficile colitis. Br Med J (1979) 1.56
Genomic organization and molecular characterization of Clostridium difficile bacteriophage PhiCD119. J Bacteriol (2006) 1.51
Pseudomembranous colitis in a leukaemia unit: a report of five fatal cases. J Clin Pathol (1979) 1.46
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One (2012) 1.40
Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS One (2016) 1.40
Clostridium difficile in association with sporadic diarrhoea. Br Med J (Clin Res Ed) (1982) 1.40
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Evaluation of eight cephalosporins in hamster colitis model. Antimicrob Agents Chemother (1981) 1.35
Spectrum of antibiotic-associated diarrhoea. Gut (1981) 1.34
Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect Immun (1987) 1.34
Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun (1982) 1.33
Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl Environ Microbiol (1979) 1.21
Inflammatory bowel disease associated circulating immune complexes. Gut (1980) 1.19
Agglutinins to bacteria in Crohn's disease. Gut (1980) 1.19
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother (2004) 1.13
Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol (1994) 1.12
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Antimicrobial susceptibilities of Clostridium difficile. J Clin Pathol (1980) 1.10
Clostridium difficile and the microbiota. J Clin Invest (2014) 1.09
Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect (2013) 1.09
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05
Typing of Clostridium difficile causing diarrhoea in an orthopaedic ward. J Clin Pathol (1989) 1.04
Automated detection of toxigenic Clostridium difficile in clinical samples: isothermal tcdB amplification coupled to array-based detection. J Clin Microbiol (2012) 1.00
Pathogenesis of postantibiotic diarrhoea caused by Clostridium difficile: an in vitro study in the rabbit intestine. Gut (1988) 1.00
Isolation of Clostridium difficile from hospitalized patients without antibiotic-associated diarrhea or colitis. J Clin Microbiol (1982) 1.00
Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome. PLoS Comput Biol (2015) 0.99
Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing? Eur J Clin Microbiol Infect Dis (2012) 0.96
Nutritional aspects of cytotoxin production by Clostridium difficile. Appl Environ Microbiol (1993) 0.96
Fluorescent-antibody test for detection of Clostridium difficile in stool specimens. J Clin Microbiol (1982) 0.96
Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95
Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev (2015) 0.94
Bacillus pumilus in the induction of clindamycin-associated enterocolitis in guinea pigs. Infect Immun (1982) 0.93
Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis. Infect Immun (2013) 0.90
Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes. Infect Immun (1987) 0.88
The enteropathogenic Escherichia coli effector NleH inhibits apoptosis induced by Clostridium difficile toxin B. Microbiology (2010) 0.87
Loss of surface fibronectin from human lung fibroblasts exposed to cytotoxin from Clostridium difficile. Infect Immun (1983) 0.87
Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection. Dig Dis Sci (2013) 0.86
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection. Antibiotics (Basel) (2015) 0.86
In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics. Antimicrob Agents Chemother (1985) 0.85
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother (2014) 0.84
Horizontal transfer of erythromycin resistance from Clostridium difficile to Butyrivibrio fibrisolvens. Antimicrob Agents Chemother (2005) 0.83
Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo. Antimicrob Agents Chemother (1992) 0.82
Antitoxin production in antibiotic-associated colitis? J Clin Pathol (1981) 0.82
Antimicrobial agent-associated colitis and diarrhea. West J Med (1980) 0.81
Comparison of polymerase chain reaction ribotyping, toxinotyping and nutritional aspects of toxin production of Clostridium difficile strains. Biomed Rep (2014) 0.81
The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol (2014) 0.81
Clostridium difficile infection of the gut. J Clin Pathol (1996) 0.81
Surgical Management of Clostridium difficile Colitis. Clin Colon Rectal Surg (2012) 0.80
Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol (2007) 0.80
Influence of antibiotics on intestinal tract survival and translocation of environmental Pseudomonas species. Appl Environ Microbiol (1990) 0.80
Clostridium difficile glutamate dehydrogenase is a secreted enzyme that confers resistance to H2O2. Microbiology (2013) 0.80
Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. Dig Dis Sci (2017) 0.79
Using phenotype microarrays to determine culture conditions that induce or repress toxin production by Clostridium difficile and other microorganisms. PLoS One (2013) 0.79
A Catalytic DNA Activated by a Specific Strain of Bacterial Pathogen. Angew Chem Int Ed Engl (2015) 0.78
Pseudomembranous colitis: multiple relapses after treatment with metronidazole. Can Med Assoc J (1981) 0.78
Antibiotic-associated colitis: an in vitro investigation of the effects of antibiotics on intestinal motility. Br J Pharmacol (1981) 0.75
Follow-up of Pseudomembranous Colitis in Children Using Colonoscopy: A Case Report. West Indian Med J (2015) 0.75
Cloning and expression of secreted antigens of Clostridium difficile in Escherichia coli. Infect Immun (1988) 0.75
A Review of Clostridium difficile Infection at the University Hospital of the West Indies, Jamaica. West Indian Med J (2015) 0.75
Comparison of culture, cytotoxin assay and two EIA tests with clinical diagnosis of Clostridium difficile-associated diarrhea. Can J Infect Dis (1994) 0.75
A cost-effective approach for detection of toxigenic Clostridium difficile: toxigenic culture using ChromID Clostridium difficile agar. J Clin Microbiol (2013) 0.75
Binary toxin and its clinical importance in Clostridium difficile infection, Belgium. Eur J Clin Microbiol Infect Dis (2016) 0.75
Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B. Biochem Biophys Rep (2017) 0.75
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
An objective and standardized test of hand function. Arch Phys Med Rehabil (1969) 4.67
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Management of anaerobic infections. Ann Intern Med (1975) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 3.13
Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci U S A (1981) 3.09
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A (1991) 2.71
Instruments for screening for depression and dementia in a long-term care facility. J Am Geriatr Soc (1989) 2.68
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Anaerobic infections of the lung and pleural space. Am Rev Respir Dis (1974) 2.46
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg (1977) 2.36
Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun (1981) 2.34
Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals. Infect Immun (1974) 2.33
Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer (1990) 2.32
Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis (1980) 2.31
Rapid microbiological assay for chloramphenicol and tetracyclines. Antimicrob Agents Chemother (1976) 2.26
Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol (1989) 2.18
Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med (2001) 2.17
Clostridium difficile in gnotobiotic mice. Infect Immun (1980) 2.17
AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med (1991) 2.13
Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A (1988) 2.12
Origins of the sex difference in human urinary free cortisol excretion. Ann Clin Biochem (1996) 2.06
Methods for quantitative vaginal flora studies. Am J Obstet Gynecol (1977) 2.05
Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis (1983) 2.03
Bacteriology of empyema. Lancet (1974) 2.00
Probenecid and zidovudine metabolism. Lancet (1989) 1.99
Cellular origin and interactions involved in gamma-interferon production induced by OKt3 monoclonal antibody. J Immunol (1982) 1.99
Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology (1978) 1.98
Infection rates in surgical neonates and infants receiving parenteral nutrition: a five-year prospective study. J Hosp Infect (2002) 1.96
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology (1988) 1.93
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother (1980) 1.89
Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med (2001) 1.89
Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet (1987) 1.88
Is Clostridium difficile endemic in chronic-care facilities? Lancet (1986) 1.88
Anaerobes survive in clinical specimens despite delayed processing. J Clin Microbiol (1976) 1.87
Purification of Shigella dysenteriae 1 (Shiga)-like toxin from Escherichia coli O157:H7 strain associated with haemorrhagic colitis. Lancet (1983) 1.87
Neonatal mouse model of group B streptococcal infection. J Infect Dis (1992) 1.82
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1987) 1.82
Update on Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Hopkins HIV Rep (1999) 1.81
The role of the intestinal microflora in experimental colitis. Am J Clin Nutr (1977) 1.80
What is clinical leadership and why might it be important in dentistry? Br Dent J (2013) 1.78
Detection of Clostridium botulinum type A toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals. J Clin Microbiol (1984) 1.77
Regulation of the soxRS oxidative stress regulon. Reversible oxidation of the Fe-S centers of SoxR in vivo. J Biol Chem (1997) 1.77
Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology (1989) 1.76